ASX - By Stock
|
RCE |
Re:
Ann: Anti-Infective Research Unit est. at Murdoch Children's
|
|
lonade
|
38 |
16K |
13 |
15/12/22 |
15/12/22 |
ASX - By Stock
|
38
|
16K
|
13
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Dr Philip Sutton - V.P. of Translational Sciences
|
|
lonade
|
17 |
8.4K |
5 |
20/07/22 |
20/07/22 |
ASX - By Stock
|
17
|
8.4K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Dr Philip Sutton - V.P. of Translational Sciences
|
|
lonade
|
17 |
8.4K |
7 |
12/07/22 |
12/07/22 |
ASX - By Stock
|
17
|
8.4K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Dr Philip Sutton - V.P. of Translational Sciences
|
|
lonade
|
17 |
8.4K |
5 |
11/07/22 |
11/07/22 |
ASX - By Stock
|
17
|
8.4K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I Positive Safety Data - 4000mg Complete
|
|
lonade
|
46 |
19K |
10 |
30/06/22 |
30/06/22 |
ASX - By Stock
|
46
|
19K
|
10
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
lonade
|
2.1K |
633K |
31 |
30/06/22 |
30/06/22 |
ASX - By Stock
|
2.1K
|
633K
|
31
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
lonade
|
2.1K |
633K |
10 |
28/06/22 |
28/06/22 |
ASX - By Stock
|
2.1K
|
633K
|
10
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
lonade
|
2.1K |
633K |
12 |
28/06/22 |
28/06/22 |
ASX - By Stock
|
2.1K
|
633K
|
12
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
lonade
|
2.1K |
633K |
7 |
28/06/22 |
28/06/22 |
ASX - By Stock
|
2.1K
|
633K
|
7
|
|
ASX - By Stock
|
AII Mining |
Re:
Waiting waiting waiting for Sangdong
|
|
lonade
|
25 |
12K |
0 |
25/06/22 |
25/06/22 |
ASX - By Stock
|
25
|
12K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Expert KOL Webinar 21 June
|
|
lonade
|
6 |
2.1K |
3 |
22/06/22 |
22/06/22 |
ASX - By Stock
|
6
|
2.1K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Expert KOL Webinar 21 June
|
|
lonade
|
6 |
2.1K |
8 |
22/06/22 |
22/06/22 |
ASX - By Stock
|
6
|
2.1K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Expert KOL Webinar 21 June
|
|
lonade
|
6 |
2.1K |
6 |
22/06/22 |
22/06/22 |
ASX - By Stock
|
6
|
2.1K
|
6
|
|
ASX - By Stock
|
RCE |
Expert KOL Webinar 21 June
|
|
lonade
|
6 |
2.1K |
11 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
6
|
2.1K
|
11
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive safety data from 4th Cohort -Phase I Clinical Trial
|
|
lonade
|
20 |
8.2K |
2 |
04/04/22 |
04/04/22 |
ASX - By Stock
|
20
|
8.2K
|
2
|
|
ASX - By Stock
|
AII Mining |
Re:
Waiting waiting waiting for Sangdong
|
|
lonade
|
25 |
12K |
0 |
04/04/22 |
04/04/22 |
ASX - By Stock
|
25
|
12K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive safety data from 4th Cohort -Phase I Clinical Trial
|
|
lonade
|
20 |
8.2K |
3 |
30/03/22 |
30/03/22 |
ASX - By Stock
|
20
|
8.2K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive safety data from 4th Cohort -Phase I Clinical Trial
|
|
lonade
|
20 |
8.2K |
7 |
30/03/22 |
30/03/22 |
ASX - By Stock
|
20
|
8.2K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Safety Committee Clears PhI R327 Dose Increase
|
|
lonade
|
16 |
7.2K |
12 |
19/03/22 |
19/03/22 |
ASX - By Stock
|
16
|
7.2K
|
12
|
|
ASX - By Stock
|
RCE |
Re:
Recce Pharmaceuticals (ASX:RCE): A multi-billion-dollar sepsis solution?
|
|
lonade
|
27 |
16K |
15 |
08/03/22 |
08/03/22 |
ASX - By Stock
|
27
|
16K
|
15
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Safety Committee Clears PhI R327 Dose Increase
|
|
lonade
|
16 |
7.2K |
10 |
08/03/22 |
08/03/22 |
ASX - By Stock
|
16
|
7.2K
|
10
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Continues in 3rd Cohort PhI Clinical Trial
|
|
lonade
|
56 |
19K |
7 |
02/03/22 |
02/03/22 |
ASX - By Stock
|
56
|
19K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Continues in 3rd Cohort PhI Clinical Trial
|
|
lonade
|
56 |
19K |
11 |
24/02/22 |
24/02/22 |
ASX - By Stock
|
56
|
19K
|
11
|
|
ASX - By Stock
|
RCE |
Re:
Another interview - Proactive
|
|
lonade
|
13 |
3.8K |
12 |
16/02/22 |
16/02/22 |
ASX - By Stock
|
13
|
3.8K
|
12
|
|
ASX - By Stock
|
RCE |
Re:
Another interview - Proactive
|
|
lonade
|
13 |
3.8K |
12 |
15/02/22 |
15/02/22 |
ASX - By Stock
|
13
|
3.8K
|
12
|
|
ASX - By Stock
|
RCE |
Re:
VIDEO: RCE REPORTS POSITIVE RESULTS FROM R327 TRIALS
|
|
lonade
|
17 |
5.6K |
24 |
10/02/22 |
10/02/22 |
ASX - By Stock
|
17
|
5.6K
|
24
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Third Cohort of PI Clinical Trial
|
|
lonade
|
37 |
9.9K |
7 |
09/02/22 |
09/02/22 |
ASX - By Stock
|
37
|
9.9K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Third Cohort of PI Clinical Trial
|
|
lonade
|
37 |
9.9K |
13 |
08/02/22 |
08/02/22 |
ASX - By Stock
|
37
|
9.9K
|
13
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
lonade
|
2.1K |
633K |
5 |
07/02/22 |
07/02/22 |
ASX - By Stock
|
2.1K
|
633K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Phase 1 Clinical Trial
|
|
lonade
|
120 |
37K |
3 |
04/02/22 |
04/02/22 |
ASX - By Stock
|
120
|
37K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Phase 1 Clinical Trial
|
|
lonade
|
120 |
37K |
3 |
03/02/22 |
03/02/22 |
ASX - By Stock
|
120
|
37K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Phase 1 Clinical Trial
|
|
lonade
|
120 |
37K |
6 |
03/02/22 |
03/02/22 |
ASX - By Stock
|
120
|
37K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Phase 1 Clinical Trial
|
|
lonade
|
120 |
37K |
8 |
03/02/22 |
03/02/22 |
ASX - By Stock
|
120
|
37K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Phase 1 Clinical Trial
|
|
lonade
|
120 |
37K |
3 |
03/02/22 |
03/02/22 |
ASX - By Stock
|
120
|
37K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Phase 1 Clinical Trial
|
|
lonade
|
120 |
37K |
7 |
02/02/22 |
02/02/22 |
ASX - By Stock
|
120
|
37K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Recap of ongoing studies / tests
|
|
lonade
|
28 |
9.3K |
16 |
24/01/22 |
24/01/22 |
ASX - By Stock
|
28
|
9.3K
|
16
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
lonade
|
2.1K |
633K |
10 |
21/01/22 |
21/01/22 |
ASX - By Stock
|
2.1K
|
633K
|
10
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
lonade
|
2.1K |
633K |
3 |
20/01/22 |
20/01/22 |
ASX - By Stock
|
2.1K
|
633K
|
3
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
lonade
|
2.1K |
633K |
5 |
20/01/22 |
20/01/22 |
ASX - By Stock
|
2.1K
|
633K
|
5
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
lonade
|
2.1K |
633K |
3 |
20/01/22 |
20/01/22 |
ASX - By Stock
|
2.1K
|
633K
|
3
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
lonade
|
2.1K |
633K |
10 |
19/01/22 |
19/01/22 |
ASX - By Stock
|
2.1K
|
633K
|
10
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
lonade
|
2.1K |
633K |
7 |
19/01/22 |
19/01/22 |
ASX - By Stock
|
2.1K
|
633K
|
7
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
lonade
|
2.1K |
633K |
6 |
19/01/22 |
19/01/22 |
ASX - By Stock
|
2.1K
|
633K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Second Cohort of PI Clinical Trial
|
|
lonade
|
44 |
12K |
6 |
18/01/22 |
18/01/22 |
ASX - By Stock
|
44
|
12K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Second Cohort of PI Clinical Trial
|
|
lonade
|
44 |
12K |
2 |
18/01/22 |
18/01/22 |
ASX - By Stock
|
44
|
12K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Recap of ongoing studies / tests
|
|
lonade
|
28 |
9.3K |
9 |
14/01/22 |
14/01/22 |
ASX - By Stock
|
28
|
9.3K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Recap of ongoing studies / tests
|
|
lonade
|
28 |
9.3K |
3 |
14/01/22 |
14/01/22 |
ASX - By Stock
|
28
|
9.3K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Recap of ongoing studies / tests
|
|
lonade
|
28 |
9.3K |
2 |
14/01/22 |
14/01/22 |
ASX - By Stock
|
28
|
9.3K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Recap of ongoing studies / tests
|
|
lonade
|
28 |
9.3K |
12 |
14/01/22 |
14/01/22 |
ASX - By Stock
|
28
|
9.3K
|
12
|
|
ASX - By Stock
|
RCE |
Re:
Recap of ongoing studies / tests
|
|
lonade
|
28 |
9.3K |
15 |
14/01/22 |
14/01/22 |
ASX - By Stock
|
28
|
9.3K
|
15
|
|